<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-299 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-299</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-299</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-53490313</p>
                <p><strong>Paper Title:</strong> Tyrosine Kinase Inhibitors for EGFR Gene Mutation-Positive Non-Small Cell Lung Cancers: An Update for Recent Advances in Therapeutics</p>
                <p><strong>Paper Abstract:</strong> The presence of activating gene mutations in the epidermal growth factor receptor (EGFR) of non-small cell lung cancer (NSCLC) patients is predictive (improved progression-free survival and improved response rate) when treated with small molecule tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib and afatinib. The two most common mutations that account for greater than 85% of all EGFR gene mutations, are in-frame deletions in exon 19 (LREA deletions) and point mutations in exon 21 (L858R). Exon 18 mutations occur much less frequently at about 4% of all EGFR gene mutations. Together, deletion19 and L858R gene mutations are present in about 10% of Caucasian patients and 20â€“40% of Asian patients with NSCLC. T790M gene mutation at exon 20 is associated with acquired resistance to EGFR TKIs. Early studies showed that activating EGFR gene mutations are most common in patients with adenocarcinoma histology, women, never smokers and those of Asian ethnicity. A recent multi-center phase III trial suggested that frontline EGFR TKI therapy with afatinib is associated with improved progressionfree survival compared to chemotherapy regardless of race. Moreover, guidelines suggest EGFR testing should be conducted in all patients with lung adenocarcinoma or mixed lung cancers with an adenocarcinoma component), regardless of characteristics such as smoking status, gender, or race. The success of targeted therapies in NSCLC patients has changed the treatment paradigm in metastatic NSCLC. However, despite a durable response of greater than a year, resistance to EGFR TKIs inevitably occurs. This mini-review describes the clinically significant EGFR gene mutations and the efficacy of small molecule EGFR TKIs as targeted therapies for these gene mutations. Therapeutic strategies to overcome resistance, including selected emerging and novel therapies are discussed. Journal of Pharmacovigilance Jo ur na l of Pharmacoilance</p>
                <p><strong>Cost:</strong> 0.012</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e299.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e299.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR mutation prevalence (Asian vs Caucasian)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Prevalence of sensitizing EGFR exon 19 deletions and exon 21 L858R mutations in NSCLC by ethnicity</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Review-reported prevalence indicating sensitizing EGFR mutations (combined exon 19 deletions and exon 21 L858R) occur substantially more often in East Asian patients with NSCLC than in Caucasian patients, and these mutations are enriched in adenocarcinoma, women, and never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Asian; Caucasian (multiple studies aggregated in review)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>mixed / various (review of multiple international studies)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Asians: ~20-40% (combined sensitizing exon 19 deletions + exon 21 L858R); Caucasians: ~10% (combined sensitizing exon 19 deletions + exon 21 L858R)</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Exon 19 in-frame deletions (LREA) ~45% of EGFR mutations; Exon 21 L858R ~40% of EGFR mutations; Exon 18 G719X ~4%; Exon 20 T790M associated with acquired resistance (frequent as resistance mechanism)</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>Asians: 20-40% (sensitizing exon19 + exon21) vs Caucasians: ~10% (sensitizing exon19 + exon21)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>More common in never or light smokers</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>More common in females</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>No specific mechanistic explanation for the ethnic difference is proposed in this review; it notes the association with clinical features (adenocarcinoma, female sex, never-smoker, Asian ethnicity) and recommends universal EGFR testing regardless of race.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>NSCLC, particularly adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Mutation-positive patients (sensitizing mutations) show high response rates (up to ~80% in selected mutation-positive cohorts) and improved progression-free survival with EGFR TKIs; the LUX-Lung 3 trial suggested PFS benefit with afatinib vs chemotherapy regardless of race.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e299.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e299.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR mutation associations (clinicopathologic)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Associations of EGFR activating mutations with adenocarcinoma histology, female sex, never-smoking status and Asian ethnicity</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper reports that activating (sensitizing) EGFR mutations are most commonly observed in lung adenocarcinomas and are enriched among women, never/light smokers, and patients of Asian ethnicity, correlating with higher TKI responsiveness.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>mixed (statements derived from pooled/early studies across populations)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>various / international (review-level statement)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Primarily exon 19 deletions and exon 21 L858R (major sensitizing mutations); also G719X (exon 18) and less commonly exon 20 insertions and T790M (resistance)</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>Paper reiterates higher prevalence in Asians (20-40%) vs Caucasians (~10%) for the main sensitizing mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Enriched in never-smokers / light smokers (i.e., mutations are more frequent in individuals who never smoked)</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Enriched in females</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>Notes correlation with smoking status (more frequent in never-smokers), but does not attribute ethnic differences specifically to lifestyle factors.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>No explicit hypotheses offered in this review for why ethnicity is associated with higher prevalence (e.g., no detailed discussion of genetic predisposition, environmental exposures, or detection bias).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Adenocarcinoma (subset of NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Mutation-positive subgroups enriched by these clinicopathologic features demonstrate higher objective response rates and longer PFS on EGFR TKIs (up to ~80% RR reported in selected mutation-positive patients).</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer <em>(Rating: 2)</em></li>
                <li>Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR <em>(Rating: 2)</em></li>
                <li>Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <em>(Rating: 2)</em></li>
                <li>Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a mutlicentre, open-label, randomized phase 3 trial. <em>(Rating: 2)</em></li>
                <li>Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>